Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMasanas Jimenez, Marc
dc.contributor.authorMasia Fandos, Nuria
dc.contributor.authorSuarez Cabrera, Leticia
dc.contributor.authorOlivan Riera, Mireia
dc.contributor.authorSoriano Fernández, Aroa
dc.contributor.authorMajem Cavaller, Blanca
dc.contributor.authorJimenez Jimenez, Carlos Gonzalo
dc.contributor.authorBoloix Amenós, Ariadna
dc.contributor.authorToledano Martin, Ignasi
dc.contributor.authorGuillén Burrieza, Gabriela
dc.contributor.authorNavarro Jimenez, Alexandra
dc.contributor.authorSánchez de Toledo Codina, Josep
dc.contributor.authorRoma Castanyer, Josep
dc.contributor.authorMoreno Martín-Retortillo, Lucas
dc.contributor.authorGallego Melcón, Soledad
dc.contributor.authorSantamaria Margalef, Anna
dc.contributor.authorSegura Ginard, Miguel
dc.date.accessioned2022-05-06T12:52:33Z
dc.date.available2022-05-06T12:52:33Z
dc.date.issued2021-10
dc.identifier.citationMasanas M, Masiá N, Suárez-Cabrera L, Olivan M, Soriano A, Majem B, et al. The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Clin Transl Med. 2021 Oct;11(10):e533.
dc.identifier.issn2001-1326
dc.identifier.urihttp://hdl.handle.net/11351/7492
dc.descriptionKIF11 inhibitor; Targeted therapies; Metastasis
dc.description.abstractIn summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesClinical and Translational Medicine;11(10)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMedicació oral
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subjectNeuroblastoma - Tractament
dc.subject.meshNeuroblastoma
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Agents
dc.subject.meshAdministration, Oral
dc.titleThe oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/ctm2.533
dc.subject.decsneuroblastoma
dc.subject.decs/farmacoterapia
dc.subject.decsantineoplásicos
dc.subject.decsadministración oral
dc.relation.publishversionhttps://doi.org/10.1002/ctm2.533
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Masanas M, Soriano A, Jiménez C, Boloix A, Roma J, Segura MF] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Masiá N, Suárez-Cabrera L, Majem B, Toledano I, Santamaria A] Laboratori de Cicle Cel•lular i Càncer, Grup de Recerca Biomèdica en Urologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Olivan M] Laboratori de Cicle Cel•lular i Càncer, Grup de Recerca Biomèdica en Urologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Translational Oncology Laboratory, Anatomy Unit, Department of Pathology and Experimental Therapy, School of Medicine, Universitat de Barcelona (UB), L’Hospitalet de Llobregat, Spain. [Guillén G] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Navarro A] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Sánchez de Toledo J] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Catalan Institute of Oncology (ICO), Barcelona, Spain. [Moreno L, Gallego S] Grup de Recerca Translacional en Càncer en la Infància i l’Adolescència, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Oncologia i Hematologia Pediàtriques, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid34709738
dc.identifier.wos000711947800022
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F00530
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F02248
dc.relation.projectidinfo:eu-repo/grantAgreement/ES/PE2013-2016/CPII18%2F00027
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record